,

Rev Esp Quimioter 2022;35(Suppl.3):20-24

Important aspects during management of diabetic foot infection

JOSÉ LUIS GARCÍA KLEPZIG, JAVIER AZAÑA GÓMEZ, MANUEL MÉNDEZ BAILÓN

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.05.2022

Diabetic foot is a complex disease. One of its most important complications is infection with risk of limb loss. In severe cases it is also a life-threatening condition. Several guidelines are available in order to achieve the implementation of some standard of care strategies. However, these consensus documents do not address all controversial issues arising during diabetic foot infection. The present article aims to review some of these controversial aspects.

Rev Esp Quimioter 2022; 35(Suppl.3):20-24 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.3):16-19

Neutralizing antibodies for SARS-CoV-2 infection

JUAN BERENGUER

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.04.2022

The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression. mAbs have also been effective for treating severe disease in seronegative patients and preventing COVID-19. So far, studies have been carried out in a largely unvaccinated population at a time when the omicron variant was not described. Future research should address these limitations and provide information on specific population groups, including immunosuppressed and previously infected individuals.

Rev Esp Quimioter 2022; 35(Suppl.3):16-19 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.3):10-15

Antiviral drugs against SARS-CoV-2

TOMMASO FRANCESCO AIELLO, CAROLINA GARCÍA-VIDAL, ALEX SORIANO

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.03.2022

The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 days that is the window of opportunity for giving an antiviral. Accordingly, early and rapid diagnostic of the infection in the outpatient clinic is essential as well as the availability of oral agents that can be easily prescribe. Remdesivir has demonstrated its efficacy in hospitalized patients requiring oxygen support and in mild/moderate cases to avoid the hospitalization, however, the intravenous administration limits its use among outpatients. Molnupiravir and nirmatrelvir/ritonavir are potent oral antiviral agents. In the present review we discuss the potential targets against SARS-CoV-2, and an overview of the main characteristics and clinical results with the available antiviral agents for the treatment of SARS-CoV-2.

Rev Esp Quimioter 2022; 35(Suppl.3):10-15 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.3):6-9

Management of hyperinflammation in COVID-19 patients

BORJA SUBERVIOLA, ELENA CUENCA FITO

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.02.2022

In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of uncontrolled hyperinflammation called cytokine storm. This cytokine storm can cause ARDS or multi-organ failure leading to patient death. This review exposes the different mechanisms of the inflammatory response in COVID-19 infection and the therapeutic options to treat this process.

Rev Esp Quimioter 2022; 35(Suppl.3):6-9 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.3):2-5

Vulnerability to SARS-CoV-2 infection and disease: ripping the curl after the storm

PABLO BARREIRO, JESÚS SAN ROMÁN ‎

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.01.2022

SARS-CoV-2 infection now seems to have entered the announced endemic phase. The population’s immunity is increasingly more robust, thanks to successive vaccination and booster campaigns, and the almost inevitable exposure and re-exposure to the virus itself, which has truly served as a natural immunizing mechanism. On the other hand, the genetic drift of the virus is leading it to become another catarrhal agent, as are the other endemic human coronaviruses. However, it should not be lost sight of that there are still segments of the population with susceptibility to severe COVID, who will be candidates to continue receiving vaccine boosters or antiviral drugs in the initial stages of infection.

Rev Esp Quimioter 2022; 35(Suppl.3):2-5 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):579-580

Peritonitis por Clostridium baratii en paciente cirrótico

LAUDY RIVERO-RODRÍGUEZ, MARGARITA BOLAÑOS-RIVERO, JESÚS MANUEL RODRÍGUEZ DE LEÓN, ISABEL DE MIGUEL MARTÍNEZ

Published: 21 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/051.2022

Rev Esp Quimioter 2022; 35(6):579-580  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):581-583

Micosis pulmonar crónica por Paracoccidioides brasiliensis

MARÍA ÁNGELES ASENCIO EGEA, JEAN CARLOS MÉNDEZ GONZÁLEZ, JORGE GAITÁN PITERA, JOSÉ MARÍA LÓPEZ-PINTOR HUERTAS, JAVIER SÁNCHEZ LÓPEZ, MARÍA HUERTAS VAQUERO

Published: 19 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/057.2022

Rev Esp Quimioter 2022; 35(6):581-583  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):589-591

Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients

IGNACIO PÉREZ CATALÁN, SERGIO GARCÍA MUÑOZ, CELIA ROIG MARTÍ, IRIS GÓMEZ ALFARO, LUIS SERRANO PICAZO, MIGUEL TORRES GARCÍA, ROBERTO REIG VALERO, RAÚL FERRANDO PIQUERES, LIDÓN MATEU CAMPOS, JOSÉ MANUEL RAMOS RINCÓN, JORGE USÓ BLASCO

Published: 18 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/078.2022

Rev Esp Quimioter 2022; 35(6):589-591  [Texto completo PDF] [Full-text PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):584-586

Cellulitis due to Pasteurella stomatis and Actinomyces canis following dog bite

DOMINGO FERNÁNDEZ-VECILLA, CRISTINA ASPICHUETA-VIVANCO, JOSÉ LUIS DÍAZ DE TUESTA-DEL ARCO

Published: 17 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/067.2022

Rev Esp Quimioter 2022; 35(6):584-586  [Full-text PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):566-569

Eumicetomas por Fusarium oxysporum y Madurella mycetomatis. Descripción de dos casos y revisión de la bibliografía

DIEGO MARTÍNEZ LÓPEZ, ANTONIO PÉREZ BLASCO, LUIS GARCÍA FERRER, JUAN J CAMARENA, ROSA GONZÁLEZ, JOSÉ LUIS RODRIGO PEREZ

Published: 17 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/027.2022

Rev Esp Quimioter 2022; 35(6):566-569  [Texto completo PDF]


/por